TiGenix : invited to present Cx611 Phase IIa data in plenary session of American College of Rheumatology and participating in

   TiGenix : invited to present Cx611 Phase IIa data in plenary session of
   American College of Rheumatology and participating in other upcoming key

                                                         Regulated information
                                                            SEPTEMBER 10, 2013

TiGenix invited to present Cx611 Phase IIa data in plenary session of American
                           College of Rheumatology
             and participating in other upcoming key conferences

Leuven (BELGIUM) - September 10, 2013 - TiGenix (NYSE Euronext: TIG), a leader
in the field  of cell therapy,  announced today  that it has  been invited  to 
present the results of its Phase  IIa study of Cx611 in refractory  rheumatoid 
arthritis in a plenary session of the American College of Rheumatology  Annual 
Meeting on  October 29.  Furthermore,  during the  second  half of  2013,  the 
company will be  present at  a number  of key events  in Europe  and the  U.S. 
geared  at  investor,  industry,  and  academic  audiences  to  highlight  the 
commercial potential of  ChondroCelect®, the  first approved  cell therapy  in 
Europe, and  of  the  company's proprietary  allogeneic  stem  cell  programs. 
TiGenix's lead product Cx601 is currently  in Phase III for perianal  fistulas 
in Crohn's disease patients.

September 15- 18
ICRS 2013, Izmir, Turkey
TiGenix Satellite Symposium -  Science & evidence  in knee cartilage  therapy: 
"Mind the Gap: Quick Fix vs. Durable Repair"
Chair: Tim  Spalding (UK)  MBBS.  FRCS, FRCS  Orth. Specialist  Knee  Surgeon, 
University Hospitals Coventry and  Warwickshire NHS Trust. Honorary  Associate 
Professor, Warwick Medical School, University of Warwick
Presenters:  Philipp   Niemeyer,  Department   of  Orthopaedic   Surgery   and 
Traumatology, Freiburg University Hospital, Freiburg, Germany; Peter  Verdonk, 
Professor of Orthopaedics and Traumatology, Ghent University, Belgium
Date & time: Tuesday, September 17, 1-2 PM

September 17-19
BioPharm America 2013, Westin Boston Waterfront Hotel, Boston, USA
Attendee: Claudia Jimenez, Senior Director Business Development

October 2-3
13th Large & Midcap Event, Palais Brongniart, Paris, France
Attendee: Claudia D'Augusta, CFO

October 14-16
Stem Cell Meeting on the Mesa, La Jolla, California, USA
Presenter: Eduardo Bravo, CEO

October 23-25
The World Conference on Regenerative Medicine, Congress Center Leipzig,
Presenter: Guido Schopen, VP Medical Affairs & Commercial Operations

October 25-28
European Society of Gene and Cell Therapy (ESGCT) Collaborative Congress '13,
Palacio Municipal de Congresos, Madrid, Spain
Presenters: Wilfried Dalemans, CTO & María Pascual, VP Clinical Operations and
Regulatory Affairs

October 25-30
American College  of  Rheumatology  (ACR)  Annual  Meeting  2013,  San  Diego, 
California, USA
Presenter: Dr.  José María  Álvaro-Gracia,  MD, PhD,  Head of  the  Biological 
Therapies Unit, Hospital Universitario de La Princesa, Madrid, Spain
Session Name: ACR Plenary Session III: Discovery 2013
Presentation: Phase  Ib/IIa Study  On Intravenous  Administration Of  Expanded 
Allogeneic Adipose-Derived  Mesenchymal Stem  Cells In  Refractory  Rheumatoid 
Arthritis Patients
Date & time: Tuesday, October 29, 2013: 11:00 AM-12:30 PM

November 4-6
BIO-Europe 2013, Messe Wien Exhibition and Congress Center, Vienna, Austria
Attendee: Claudia Jimenez, Senior Director Business Development

November 14
2nd Edition Belgian Biotech & Pharma Seminar, The Grand Hyatt, New York, USA
Attendee: Eduardo Bravo, CEO

November 21-24
IFATS meeting, Conrad New York, USA
Presenter: Dr. Gonzalez-Argente,MD, Head of Surgery Department, Hospital
Universitari Son Espases, Palma, Spain
Presentation: Expanded allogeneic adipose-derived stem cells for the treatment
of complex perianal fistula in Crohn's disease: results from a multicenter
Phase I/IIa clinical trial
Date & time: Saturday, November 23: 8:12 AM

Presenter: Eleuterio Lombardo, Scientific Director TiGenix
Presentation: Intralymphatic administration of adipose msenchymal stem cells
shows therapeutic effect in experimental colitis and arthritis
Date & time: Saturday, November 23, 3 PM

For more information:
Eduardo Bravo
Chief Executive Officer

Claudia D'Augusta
Chief Financial Officer

Hans Herklots
Director Investor & Media Relations
+32 16 39 60 97

About TiGenix

TiGenix NV (NYSE Euronext  Brussels: TIG) is a  leading European cell  therapy 
company with a marketed  product for cartilage  repair, ChondroCelect®, and  a 
strong pipeline with clinical  stage allogeneic adult  stem cell programs  for 
the treatment of autoimmune and inflammatory diseases. TiGenix is based out of
Leuven (Belgium) and has operations in Madrid (Spain), and Sittard-Geleen (the
Netherlands). For more information please visit www.tigenix.com.

Forward-looking information

This document  may  contain  forward-looking  statements  and  estimates  with 
respect to the  anticipated future performance  of TiGenix and  the market  in 
which it operates. Certain of these statements, forecasts and estimates can be
recognised by  the  use of  words  such as,  without  limitation,  "believes", 
"anticipates", "expects",  "intends",  "plans", "seeks",  "estimates",  "may", 
"will" and "continue" and similar  expressions. They include all matters  that 
are not historical facts. Such  statements, forecasts and estimates are  based 
on  various  assumptions   and  assessments  of   known  and  unknown   risks, 
uncertainties and other factors,  which were deemed  reasonable when made  but 
may or may not prove to be correct. Actual events are difficult to predict and
may depend upon factors  that are beyond  TiGenix' control. Therefore,  actual 
results, the financial condition, performance  or achievements of TiGenix,  or 
industry results, may  turn out  to be  materially different  from any  future 
results, performance or achievements expressed or implied by such  statements, 
forecasts and  estimates. Given  these uncertainties,  no representations  are 
made as  to  the accuracy  or  fairness of  such  forward-looking  statements, 
forecasts and  estimates. Furthermore,  forward-looking statements,  forecasts 
and estimates only speak as of the  date of the publication of this  document. 
TiGenix disclaims any obligation to update any such forward-looking statement,
forecast or  estimates to  reflect any  change in  TiGenix' expectations  with 
regard thereto, or any change in events, conditions or circumstances on  which 
any such  statement, forecast  or  estimate is  based,  except to  the  extent 
required by Belgian law.


This announcement is distributed by Thomson Reuters on behalf of Thomson
Reuters clients.

The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other
applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of
information contained therein.

Source: TiGenix via Thomson Reuters ONE
Press spacebar to pause and continue. Press esc to stop.